Novartis AG ADR - Asset Resilience Ratio
Novartis AG ADR (NVS) has an Asset Resilience Ratio of 10.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2025)
This chart shows how Novartis AG ADR's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Novartis AG ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $11.44 Billion | 9.89% |
| Short-term Investments | $155.00 Million | 0.13% |
| Total Liquid Assets | $11.59 Billion | 10.03% |
Asset Resilience Insights
- Moderate Liquidity: Novartis AG ADR has 10.03% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Novartis AG ADR Industry Peers by Asset Resilience Ratio
Compare Novartis AG ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 10.04% |
|
Chongqing Lummy Pharmaceutical
SHE:300006 |
Drug Manufacturers - General | -0.19% |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507 |
Drug Manufacturers - General | 24.96% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.09% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
Annual Asset Resilience Ratio for Novartis AG ADR (1998–2025)
The table below shows the annual Asset Resilience Ratio data for Novartis AG ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.13% | $155.00 Million | $115.57 Billion | -10.40pp |
| 2024-12-31 | 10.53% | $10.77 Billion | $102.25 Billion | -0.23pp |
| 2023-12-31 | 10.76% | $10.76 Billion | $99.94 Billion | -2.64pp |
| 2022-12-31 | 13.40% | $15.74 Billion | $117.45 Billion | -5.35pp |
| 2021-12-31 | 18.75% | $24.72 Billion | $131.79 Billion | +12.84pp |
| 2020-12-31 | 5.91% | $7.81 Billion | $132.19 Billion | -1.01pp |
| 2019-12-31 | 6.92% | $8.20 Billion | $118.41 Billion | -1.90pp |
| 2018-12-31 | 8.82% | $12.84 Billion | $145.56 Billion | +3.93pp |
| 2017-12-31 | 4.90% | $6.51 Billion | $133.08 Billion | +0.39pp |
| 2016-12-31 | 4.51% | $5.87 Billion | $130.12 Billion | +3.92pp |
| 2015-12-31 | 0.59% | $773.00 Million | $131.56 Billion | -0.08pp |
| 2014-12-31 | 0.67% | $839.00 Million | $125.39 Billion | -1.34pp |
| 2013-12-31 | 2.01% | $2.54 Billion | $126.25 Billion | -0.06pp |
| 2012-12-31 | 2.07% | $2.57 Billion | $124.22 Billion | +0.90pp |
| 2011-12-31 | 1.16% | $1.37 Billion | $117.50 Billion | -1.12pp |
| 2010-12-31 | 2.28% | $2.81 Billion | $123.32 Billion | -12.96pp |
| 2009-12-31 | 15.24% | $14.55 Billion | $95.50 Billion | +10.03pp |
| 2008-12-31 | 5.21% | $4.08 Billion | $78.30 Billion | -5.18pp |
| 2007-12-31 | 10.39% | $7.84 Billion | $75.45 Billion | +4.30pp |
| 2006-12-31 | 6.09% | $4.14 Billion | $68.01 Billion | -1.90pp |
| 2005-12-31 | 7.99% | $4.61 Billion | $57.73 Billion | -7.63pp |
| 2004-12-31 | 15.62% | $8.51 Billion | $54.47 Billion | +0.19pp |
| 2003-12-31 | 15.44% | $7.61 Billion | $49.32 Billion | +0.46pp |
| 2002-12-31 | 14.98% | $6.76 Billion | $45.14 Billion | -1.04pp |
| 2001-12-31 | 16.02% | $6.46 Billion | $40.30 Billion | -4.12pp |
| 2000-12-31 | 20.14% | $7.15 Billion | $35.48 Billion | +4.81pp |
| 1999-12-31 | 15.33% | $6.32 Billion | $41.21 Billion | +3.82pp |
| 1998-12-31 | 11.52% | $4.63 Billion | $40.21 Billion | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more